Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
8569444
Reference Type
Journal Article
Title
A current review of COVID-19 for the cardiovascular specialist
Author(s)
Lang, JP; Wang, X; Moura, FA; Siddiqi, HK; Morrow, DA; Bohula, EA
Year
2020
Is Peer Reviewed?
Yes
Journal
American Heart Journal
ISSN:
0002-8703
EISSN:
1097-6744
Volume
226
Page Numbers
29-44
Language
English
DOI
10.1016/j.ahj.2020.04.025
URL
https://www.proquest.com/scholarly-journals/current-review-covid-19-cardiovascular-specialist/docview/2410352139/se-2?accountid=171501
Exit
Abstract
Although coronavirus disease 2019 (COVID-19) predominantly disrupts the respiratory system, there is accumulating experience that the disease, particularly in its more severe manifestations, also affects the cardiovascular system. Cardiovascular risk factors and chronic cardiovascular conditions are prevalent among patients affected by COVID-19 and associated with adverse outcomes. However, whether pre-existing cardiovascular disease is an independent determinant of higher mortality risk with COVID-19 remains uncertain. Acute cardiac injury, manifest by increased blood levels of cardiac troponin, electrocardiographic abnormalities, or myocardial dysfunction, occurs in up to ~60% of hospitalized patients with severe COVID-19. Potential contributors to acute cardiac injury in the setting of COVID-19 include (1) acute changes in myocardial demand and supply due to tachycardia, hypotension, and hypoxemia resulting in type 2 myocardial infarction; (2) acute coronary syndrome due to acute atherothrombosis in a virally induced thrombotic and inflammatory milieu; (3) microvascular dysfunction due to diffuse microthrombi or vascular injury; (4) stress-related cardiomyopathy (Takotsubo syndrome); (5) nonischemic myocardial injury due to a hyperinflammatory cytokine storm; or (6) direct viral cardiomyocyte toxicity and myocarditis. Diffuse thrombosis is emerging as an important contributor to adverse outcomes in patients with COVID-19. Practitioners should be vigilant for cardiovascular complications of COVID-19. Monitoring may include serial cardiac troponin and natriuretic peptides, along with fibrinogen, D-dimer, and inflammatory biomarkers. Management decisions should rely on the clinical assessment for the probability of ongoing myocardial ischemia, as well as alternative nonischemic causes of injury, integrating the level of suspicion for COVID-19.
Keywords
Antimalarials; Antiviral Agents; Biomarkers; Receptor, Angiotensin, Type 2; remdesivir; 3QKI37EEHE; Adenosine Monophosphate; 415SHH325A; Hydroxychloroquine; 4QWG6N8QKH; Chloroquine; 886U3H6UFF; Alanine; OF5P57N2ZX; Abridged Index Medicus; Index Medicus; Adenosine Monophosphate -- analogs & derivatives; Biomarkers -- blood; Hypoxia -- complications; Pandemics; Receptor, Angiotensin, Type 2 -- metabolism; Risk Factors; Alanine -- analogs & derivatives; Virus Internalization; COVID-19; Takotsubo Cardiomyopathy -- etiology; Antimalarials -- therapeutic use; Antiviral Agents -- therapeutic use; Chloroquine -- therapeutic use; SARS-CoV-2; Hydroxychloroquine -- therapeutic use; Adenosine Monophosphate -- therapeutic use; Alanine -- therapeutic use; Plasma -- immunology; Betacoronavirus -- pathogenicity; Pneumonia, Viral -- complications; Coronavirus Infections -- complications; Pneumonia, Viral -- drug therapy; Betacoronavirus -- immunology; Cardiovascular Diseases -- complications; Coronavirus Infections -- drug therapy
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity